Where Will CRISPR Therapeutics Be in 3 Years?
CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior successes to become a biotech powerhouse and prove to investors that it isn't a one-trick pony.
The next three years will be critical for both of those things. Here's what to expect.
By late 2027, CRISPR will be a larger biotech, with much more revenue, more collaborators, and a much bigger pipeline -- but still probably not any profits.
Source Fool.com
